Autoinflammatory & rare systemic diseases
Diagnosis, management, and monitoring of interleukin-1 mediated diseases in Central and Eastern Europe: real-world data
Authors' conclusion
Adherence to the 2021 EULAR/ACR recommendations for IL-1-mediated autoinflammatory diseases is achievable in Central and Eastern European countries.
Study context
- Population
- Representatives from 10 Central and Eastern European countries addressing autoinflammatory diseases, 202310 countries
- Exposure
- Current practice vs 2021 EULAR/American College of Rheumatology (ACR) recommendations for IL-1-mediated autoinflammatory diseases
- Outcome
- Diagnostic, treatment and follow-up options for IL-1-mediated autoinflammatory diseases compared with 2021 EULAR/ACR recommendations
Methodological detailsstructured collaborative effort, multinational, 10 Central and Eastern European countries
- Structured collaborative effort
- Multinational
- 10 Central and Eastern European countries
Main finding
As reported in the abstract
- Specialised centres for diagnosis and treatment in almost all countries; care by rheumatologists and/or clinical immunologists
- Genetic testing available in all countries, with variation in test types
- Massive parallel sequencing panels available in all countries; waiting for results 3 to 6 months in most cases
- Availability of disease-specific laboratory assessments (e.g. S100 proteins) limited
- IL-1 inhibitors available in all countries; licensing and reimbursement of anakinra and canakinumab differ by indication or diagnosis
- Transition typically starts around age 18 or beyond in most countries; no structured transition programme in the majority
Observational data: associations, not effects.
Original publication
Diagnosis, management, and monitoring of interleukin-1 mediated diseases in Central and Eastern Europe: real-world data. Pediatr Rheumatol Online J. Published 23 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →